Detalhe da pesquisa
1.
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Blood
; 143(9): 786-795, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946283
2.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
N Engl J Med
; 386(15): 1421-1431, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417637
3.
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
Br J Haematol
; 200(6): 722-730, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482815
4.
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hematol Oncol
; 41(5): 848-857, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496298
5.
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Oncologist
; 27(8): 625-636, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552754
6.
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Blood
; 133(2): 147-155, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478094
7.
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).
Am J Hematol
; 96(12): 1639-1646, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653287
8.
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Br J Haematol
; 190(6): 933-938, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33439486
9.
Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Future Oncol
; 15(3): 297-303, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30301373
10.
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
Br J Haematol
; 180(3): 365-373, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29193021
11.
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Breast Cancer Res Treat
; 167(3): 671-686, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29063313
12.
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Blood
; 127(26): 3360-8, 2016 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27207788
13.
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Future Oncol
; 14(14): 1387-1396, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29421926
14.
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Cancer
; 123(6): 994-1002, 2017 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28094841
15.
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
Br J Haematol
; 177(2): 254-262, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28169430
16.
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Blood
; 126(26): 2798-804, 2015 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377597
17.
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Support Care Cancer
; 25(11): 3295-3304, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842778
18.
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
Br J Haematol
; 195(4): e150-e153, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611900
19.
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Oncologist
; 21(3): 279-80, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26911408
20.
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
BMC Cancer
; 16: 166, 2016 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26921245